Investor Moves
| Name | Value | Action | Change | Price | Last Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $9M169.1k shares AddQ1 2026 $5M $51.87 $54.64 | |||||
Ken GriffinCitadel Advisors $701.5K AddQ4 2025 $701k -- $54.64 | |||||
News
gurufocus.comWuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Marketgurufocus.comJun 18
gurufocus.comNew TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelgurufocus.comJun 13
gurufocus.comWuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facilitygurufocus.comJun 4
gurufocus.comJohnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 studygurufocus.comJun 3
gurufocus.comJohnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseasegurufocus.comJun 3